Small Cap Feast

7th November 2023

Dish of the day
No Joiners today
Off the menu
No leavers today
Dish Of The Day:

No joiners today.

No leavers today.

What’s Cooking In The IPO Kitchen?

Tekcapital announced intention to spin off and IPO on 2 October: MicroSalt, the developer of salt-producing technology designed to deliver full flavor with less sodium, announces the launch of an exempt public offer of shares to retail investors for up to £2.5m via PrimaryBid as part of its spin out from AIM listed Tekcapital plc (TEK.L). Microsalt announced revenues of US$0.638m in 2022, its first year of retail sales of SaltMe Crisp brand and Microsalt salt shakers in US based supermarkets and through Amazon US. AIM Admission delayed, expected mid-November.

Stranger Holdings announced 02 October 2023, a Company formed for the purpose of acquiring a business, project or assets announces a Proposed Acquisition of up to a 70% interest in the Henkries Uranium Deposit and Prospecting Right in the Republic of South Africa. The Company will acquire this indirect ownership via the acquisition of two intermediary holding companies, namely Mayflower Energy Metals Limited and Neo Uranium Africa Proprietary Limited. The Acquisition constitutes a Reverse Takeover under the Listing Rules since, in substance it results in a fundamental change in the business of the issuer. Trading in the Existing Ordinary Shares continues to be suspended. It is anticipated that Re-Admission and trading in the Company's Enlarged Share Capital will occur on or around 7 November 2023.

Breakfast Buffet

CloudCoCo 0.95p £6.7m (CLCO.L)
A UK provider of Managed IT services and communications solutions to private and public sector organisations, provides an update on its trading for the year ended 30 September 2023 (FY23). Revenue expected to be no less than £26.0m (FY22: £24.2m), as a result Group EBITDA expected to be in the region of £1.9m (FY22: £1.6m). The Group signed 42 new logo customers in the year (FY22: 39) and announces 110% increase in MoreCoCo ecommerce sales to £4.2m following growth initiatives. The Group are confident to gain further traction in FY24.

Croma Security Solutions Group 49p £6.7m (CSSG.L)
The innovation and service-focused security solutions provider, reports its trading results for the 12 months to 30 June 2023 (FY23). Group revenue for the Period including Vigilant of £42.83m (FY22: £35.17m), as a result, EBITDA on continuing businesses increased 73% to £0.95m (FY22: £0.55m). The Group holds net cash of £2.14m at period end. Vigilant was sold on 30 June 2023 for a total consideration of £6.5m plus intercompany balances of £1.07m. FY24 has started well with a number of new commercial orders and the ongoing sales of iLOQ.

Futura Medical 30.4p £91.5m (FUM.L)
The pharmaceutical company developing sexual health products, announces that M8 Pharmaceuticals, Inc (M8) has taken up its rights to extend its licensing agreement from Brazil and Mexico to market MED3000 in a further fourteen countries throughout the Central and South American region. Futura's commercial agreement with M8 included an option, which has been exercised, to take up exclusive development and commercialisation rights for MED3000 throughout South and Central America. Futura has received an undisclosed upfront milestone payment from M8 as part of the extended agreement.

Harland & Wolff Group Holdings 14.5p £25.1m (HARL.L)
The UK company focused on strategic infrastructure projects and physical asset lifecycle management, announces that its recently opened Miami based office has been awarded its first contract for circa $1.5m to support TampaShip part of the Edison Chouest Group, in the completion of the construction of a floating dock for the Bollinger shipyard facility in the Gulf of Mexico. Fabrication works have commenced and are expected to be completed within the next three months.

Intelligent Ultrasound 9.75p £31.9m (IUG.L)
The classroom to clinic ultrasound company, focusing on artificial intelligence (AI) software and simulation, announced that it has signed a research agreement with the University of Dundee to initiate the first phase of proof-of-concept work to develop AI-based tools for screening patients with liver disease. The agreement, which is mainly royalty-based, will allow Intelligent Ultrasound to develop ultrasound-based AI tools with the potential to support clinicians in the clinical management of metabolic dysfunction-associated steatotic liver disease and its advanced form, metabolic dysfunction-associated steatohepatitis.

Intercede Group 66p £38.4m (IGP.L)
The cybersecurity software company specialising in digital identities, announced that the Group has secured the following contract and renewal orders: New top-up licence order for MyID CMS from a existing US Defence and Aerospace manufacturer; new technology client for MyID PSM in the Middle East, new government agency for MyID MFA/PSM in the Middle East increasing the Group's reach in this country; upgrade by a large northern European Bank of MyID CMS; and renewal of a sizable support and maintenance contract with a US Federal Agency. With a contract value in excess of $1.4m, underpins the Group's revenue for FY24 and creates contracted revenue backlog for FY25.

Kromek Group 5.4p £32.4m (KMK.L)
A developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segments, announces that it has entered into a collaboration agreement with a new partner to develop Cadmium Zinc Telluride (CZT) based detectors for photon counting computed tomography application. The new blue-chip partner is a technology solutions provider to over 100,000 customers globally for a range of applications, including healthcare. As part of the collaboration, Kromek will integrate its CZT sensors with the partner's read-out electronics to ensure optimal computed tomography detection system performance.

MTI Wireless Edge 35p £30.9m (MWE.L)
The technology group focused on comprehensive communication and radio frequency solutions across multiple sectors, announces that its Distribution & Professional Consulting Services Division has received various orders for the service and maintenance of surveillance platforms from the Israeli Ministry of Defense. The combined orders are worth approximately US$1m and are to be supplied over the next 14 months.

Naked Wines 29.65p £21.9m (WINE.L)
The online wine retailer announces a trading update. Trading in the US market is weaker than anticipated, as a consequence, guidance for the current year is being reduced: revenue expectations reduced to -12% to -16% (previously -8% to -12%) and adjusted EBIT expectations reduced to £2-6m (previously £8-12m). The Group further reported in September 2023 that FY24 had started slower than expected, with Q1 revenue down 18% versus the prior year. The Group ended H1 with £3m net cash and £45m of additional liquidity available through its credit facility. Nick Devlin will step down from the Board and his role as CEO with immediate effect. Rowan Gormley, founder and Chairman, will take the role of Executive Chairman on an interim basis.

Water Intelligence 345p £59.9m (WATR.L)
A provider of precision, minimally-invasive leak detection and remediation solutions for both potable and non-potable water announces a change to its board following on from its annual American Leak Detection (ALD) Franchise Convention. The Group announces that Michael Reisman, Myres S. McDougal Professor of International Law at Yale,is retiring from the board. The Group also announces Phil Meckley, is succeeding Dr. Reisman as a Non-Executive Director. Mr. Meckley brings over twenty years of operating experience in growing ALD locations and has provided significant leadership to the entire franchise system.

7 November 2023
*A corporate client of Hybridan LLP or retained by Hybridan LLP for certain services
** Arranged by most recent first
*** Alphabetically arranged


Our daily digest of news from UK listed Small and Mid caps straight to your Inbox.


This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email with “unsubscribe me”.

© Copyright 2024 - Hybridan | Website by Boxed Up Media
First Visit
bookcrossmenu linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram